The Gilead Health Policy Advisory Board (HPAB) was established in 2007 to help guide the company’s efforts to address policy issues related to enabling access to our medications for HIV/AIDS, viral hepatitis and other life-threatening diseases, both in the United States and around the world.

HPAB members meet regularly, and provide insight and recommendations to Gilead’s senior management on how the company can best contribute to removing barriers to patient access to quality care.

HPAB members include accomplished experts and leaders in global health, public policy and medical science. Members serve in their individual capacities and do not represent the organizations with which they are affiliated. Guest speakers with special expertise in a meeting topic are frequently invited to participate in HPAB meetings.